Curant Health

Overview

Curant Health is an independent specialty pharmacy and Medication Care Management operator whose Curant Rare unit supports rare and orphan therapy programs. For manufacturer buyers, the relevant scope is pharmacy-led access: limited distribution, patient care coordination, insurance and financial-assistance navigation, shipment visibility, refill reminders, and patient-journey reporting tied to specialty fulfillment.

Curant is not a broad PBM-owned specialty pharmacy and not a standalone hub vendor. The best-fit use case is a rare-disease launch where the manufacturer wants a focused pharmacy partner that can coordinate dispensing, adherence support, and data feedback without separating those workflows across multiple vendors.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Curant Health is evaluated as independent specialty pharmacy and Medication Care Management operator whose Curant Rare unit supports rare and orphan therapy programs.

Capability	Buyer should compare	Curant Health readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Core rare-disease fit. Curant Rare is built around rare and ultra-rare populations, with public Corcept and IWILFIN signals. Relevant through Cencora. The Cencora collaboration packages Curant Rare with broader rare-disease commercialization support.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Pharmacy-led support. Public materials cite insurance navigation and financial-assistance services; validate exact hub depth by program.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Core. Curant emphasizes dedicated care coordinators, shipment visibility, refill reminders, education, and Medication Care Management.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Not the main buying reason for Curant Health; validate only if the SOW includes cold chain, rems, and complex handling.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Documented but diligence-heavy. Curant markets RWE / RWD and business intelligence; define exact fields, governance, and update cadence in the SOW.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent. Curant has provider-facing operations, but the manufacturer page should focus on rare-disease specialty fulfillment.

Buyer Fit

• Best shortlist motion: A rare-disease biotech evaluating focused specialty pharmacy partners for limited distribution, patient engagement, and manufacturer reporting.
• Best-fit buyers: Access, channel, trade, patient services, and commercial operations teams supporting orphan or ultra-orphan therapies.
• Less ideal fit: Products that require broad PBM channel leverage, large national dispense share, or a full hub-services platform independent of the specialty pharmacy.
• Commercial fit: Custom / RFP-led; scope should define specialty pharmacy services, patient support, manufacturer data feeds, and any Cencora-linked services.
• Profile signal: Curant Rare’s January 2026 Cencora collaboration and Corcept’s pharmacy-services transition make the profile more manufacturer-relevant than a generic specialty pharmacy page.
• Launch diligence: Confirm payer-network fit, LDD experience by therapy class, data-sharing fields, patient-reported-outcome methodology, and what happens when a payer requires transfer to another specialty pharmacy.

Differentiators

• Rare-disease pharmacy focus: Curant Rare was launched specifically for rare and orphan disease populations rather than broad specialty volume.
• Pharmacy plus engagement model: Patient care coordinators, insurance navigation, financial assistance, refill reminders, and education are positioned around the dispensing workflow.
• RWE / RWD positioning: Curant markets Medication Care Management as a source of real-world data and business intelligence for manufacturers.
• Cencora commercialization connection: The Cencora collaboration can give manufacturers a broader launch-support wrapper around Curant Rare’s pharmacy role.
• Independent posture: Curant is not a PBM-owned specialty pharmacy, reducing some channel-steering concerns that come with vertically integrated pharmacy parents.

RFP Questions

• Which services would Curant deliver directly, and which would be handled through Cencora or another partner?
• What payer networks, state licenses, REMS capabilities, and rare-disease LDD programs are already relevant to the proposed therapy?
• What fields are included in manufacturer reporting, and how frequently are dispense, status, adherence, abandonment, and patient-reported-outcome files delivered?
• How does Curant manage payer-mandated transfers to a different specialty pharmacy while preserving data visibility for the manufacturer?
• What evidence can Curant show for time-to-first-fill, persistence, adherence, patient satisfaction, and out-of-pocket cost reduction on comparable rare-disease programs?
• How are adverse-event observations, side-effect reports, and product-suitability feedback routed to manufacturer pharmacovigilance teams?
• What references can Curant provide from rare-disease manufacturers or commercialization partners?

Recent Activity

• 2026-01 - Curant Rare announced a strategic collaboration with Cencora to support commercialization of rare and orphan drug products.
• 2025-10 - Curant Rare announced a Corcept Therapeutics specialty pharmacy partnership for coordinated access and patient support.
• 2025-08 - Curant Rare became exclusive pharmacy partner for IWILFIN and the IWILFIN Cares support experience.
• 2025-01 - Curant Health launched Curant Rare as a business unit dedicated to rare and orphan disease care.